FIELD: pharmaceutics.
SUBSTANCE: present invention relates to pharmaceutical compositions, suitable for injection, comprising anakinra as an active compound, as well as EDTA, polysorbate 80, sodium chloride, sodium phosphate, pH 6-7, mannitol, in the absence of sodium citrate.
EFFECT: invention provides usefulness for the treatment of IL-1 mediated disorders, stability and decreasing nociceptive pain during such treatment.
1 cl, 4 dwg, 7 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING ANAKINRA | 2016 |
|
RU2728795C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL INJECTIONS | 2007 |
|
RU2432155C2 |
| STABLE LIQUID PHARMACEUTICAL PREPARATIONS OF FUSED PROTEIN TNFR: Fc | 2012 |
|
RU2614257C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE | 2011 |
|
RU2682720C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| LIQUID FORMULATIONS OF GLUCAGON ANALOGUES | 2021 |
|
RU2819934C1 |
| FLUID FORMULATION OF FOLLICLE-STIMULATING HORMONE | 2011 |
|
RU2553375C2 |
